Solve Intelligence for Biotech Patents
Solve Intelligence
Life sciences is where patent drafting stops being mostly a writing workflow and starts becoming a data structure and claim scope workflow, which is why it can support much higher pricing. In pharma and biotech, attorneys need to manage sequence listings, antibody and biologic claim support, and dense technical disclosures that must survive strict enablement and written description review. Solve already handles chemical sequences and technical drawings, which makes this a natural move beyond standard mechanical and software filings.
-
Sequence listing is its own compliance layer. Since July 1, 2022, applications with nucleotide or amino acid disclosures must use ST.26 XML sequence listings, and WIPO provides dedicated software and validation tools for this format. Product support here means generating and checking structured biotech filing data, not just drafting prose.
-
Biologics patents are hard because broad claims are scrutinized closely. USPTO guidance after Amgen v. Sanofi emphasizes enablement across the full claim scope, and EPO guidance says new antibodies to known targets are usually not inventive without a surprising effect or other special facts. That raises the value of software that helps attorneys draft narrower, better supported claims and examples.
-
This fits Solve Intelligence’s monetization and positioning. The company sells workflow software to more than 400 IP teams, uses usage based pricing tied to drafting intensity, and already supports multimodal inputs like chemical sequences and drawings. In legal AI more broadly, niche tools that embed into expensive specialist workflows can command premium budgets because they save expert hours, not just document time.
The next step is for patent AI to become specialized by claim type, not just by practice area. If Solve ships sequence listing and biologics features that attorneys trust in real filing workflows, it can move up from general patent copilot to the default drafting layer for the most expensive patent matters, where software spend is tiny relative to prosecution and portfolio value.